ABE419
Anti-Histone H3.3 Antibody, K27M mutant
from rabbit, purified by affinity chromatography
Synonym(s):
Histone H3.1, Histone H3.3
Select a Size
About This Item
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
mouse, human
technique(s)
ChIP: suitable
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
mutation (Lys27Met)
Gene Information
human ... H3F3B(3021)
General description
Immunogen
Application
- Peptide Inhibition Assay (PIA): Target band detection inlysate from HEK-293 cells transfected with Histone H3.3 K27M mutant wasprevented by pre-blocking of a representative lot with the immunogen HistoneH3.3 K27M mutant peptide, but not the corresponding unmodified Histone H3.3 peptide.
- Immunohistochemistry (IHC): A representative lot of this antibodydetected Histone 3.3 K27M in pediatric glioblastoma tissue sections. (Venneti,S., et al. (2014). Acta Neuropathol 128(5); 743-753).
Epigenetics & Nuclear Function
Histones
Biochem/physiol Actions
Physical form
Preparation Note
Analysis Note
Lysates from MEF transfectants expressing K27M (positive) or wildtype (negative) FLAG-HA-tagged histone H3.3.
Western Blotting Analysis (WB): A 1:2,000 dilution of a representative lot of thisantibody detected Histone H3.3 K27M in HEK-293 cells transfected with HistoneH3.3 K27M mutant.
Other Notes
Disclaimer
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service